DECN Today Launches its GenUltimate TGB Product into Select International Markets
DECN Awaits Major Counter Proposition from Two Entities as JNJ Litigation Heats up
LOS ANGELES, CA June 6, 2019 - Decision Diagnostics Corp. (OTC PINK: DECN) is a 17 year old, diabetes-focused FDA Registered bio-technology worldwide company has received a fourth unsolicited proposition for a strategic transaction involving our GenUltimate! TBG system, Read More. See Complete Information: http://www.thestreetnow.com/spotlight/dailynews/.....